Campianl, Jian L.; Ghosh, Subhajit; Kapoor, Vaishali; Yan, Ran; Thotala, Sukrutha; Jash, Arijita; Hu, Tong; Mahadevan, Anita; Rifai, Kasem; Pagel, Logan; Lee, Byung Ha; Ferrando-Martinez, Sara; Wolfarth, Alexandra A.; Yang, Se Hwan; Hallahan, Dennis; Chhedau, Milan G.; Thotala, Dinesh published the artcile< Long-acting recombinant human interleukin-7, NT-17, increases cytotoxic CD8 T cells and enhances survival in mouse glioma models>, Category: esters-buliding-blocks, the main research area is temozolomide NT17 anticancer agent CD8 T cell glioblastoma.
Patients with glioblastoma (GBM) are treated with radiotherapy (RT) and temozolomide (TMZ). These treatments may cause prolonged systemic lymphopenia, which itself is associated with poor outcomes. NT-17 is a long-acting IL7 that expands CD4 and CD8 T-cell numbers in humans and mice. We tested whether NT-17 prevents sys- temic lymphopenia and improves survival in mouse models of GBM. Exptl. Design: C57BL/6 mice bearing intracranial tumors (GL261 or CT2A) were treated with RT (1.8 Gy/day x 5 days), TMZ (33 mg/kg/day x 5 days), and/or NT-17 (10 mg/kg on the final day of RT). We followed the mice for survival while serially analyzing levels of circulating T lymphocytes. We assessed regulatory T cells (Treg) and cytotoxic T lymphocytes in the tumor microenvironment, cervical lymph nodes, spleen, and thymus, and hematopoietic stem and progenitor cells in the bone marrow. GBM tumor-bearing mice treated with RT+NT-17 increased T lymphocytes in the lymph nodes, thymus, and spleen, enhanced Wily production, and decreased Tregs in the tumor which was associated with a significant increase in sur- vival. NT-17 also enhanced central memory and effector memory CD8 T cells in lymphoid organs and tumor. Depleting CD8 T cells abrogated the effects of NT-17. Furthermore, NT-17 treatment decreased progenitor cells in the bone marrow. In orthotopic glioma-bearing mice, NT-17 miti- gates RT-related lymphopenia, increases cytotoxic CD8 T lympho- cytes systemically and in the tumor, and improves survival. A phase I/II trial to evaluate NT-17 in patients with high-grade gliomas is ongoing (NCT03687957).
Clinical Cancer Research published new progress about Antitumor agents. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Category: esters-buliding-blocks.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics